

Lysate Dilution (%)
6.25
12.5
25
50
100
Amplified
100
47
78
Non-amplified
16
36
12
Relative MCL1 Levels (%)
MCL1L
GAPDH
A549
H1975
H1650
H2110
H23
H1568

FIG. 1



CNTRL -Dox
CNTRL +Dox
MCL1 shRNA -Dox
MCL1 shRNA +Dox
%Growth (CTG)
150
100
50
0
NCI-H1568
NCI-H23
NCI-H2110
NCI-H1650
NCI-H1975
A549

FIG. 2




FIG. 3



mRNA Fold Change
(post 6 hr exposure)
16
4
1
0.25
0.063
0.016
0.1
10
1000
E7107 nM
MCL1 pre-mRNA
MCL1S
MCL1L

FIG. 4



E7107 (nM)
0
0.5
5
50
500
5000
-MCL1L
-truncated MCL1
-cleaved PARP
-Tubulin

FIG. 5



CNTRL
MCL1L
-
+
-
+
Dox
-MCL1L
-GAPDH

FIG. 6



NCIH1568
+Vector
+MCL1L
100
50
0
-50
-100
% Growth
0.1
1
10
100
1000
10000
E7107 (nM)

FIG. 7



BCL2L1 shRNA
Dox - +
BCL2L1 (BCL-xL)
GAPDH
A549

FIG. 8



A549 BCL2L1 shRNA -Dox
A549 BCL2L1 shRNA +Dox
% Growth
100
50
0
-50
-100
0.1
1
10
100
1000
10000
E7107 (nM)

FIG. 9



FIG. 10 CONT.
FIG. 10
FIG. 10 CONT.
FIG. 10 CONT. 1
FIG. 10 CONT. 2
NCIH23
NCIH2110
EMPTY VECTOR
SYNERGY SCORE =50.8
SYNERGY SCORE =50.2
DOSE MATRIX
LOEWE EXCESS
GROWTH INHIBITION (%) N=2
GROWTH INHIBITION (%)
VOL=14.8(.48) CH12=4400
VOL=15.2(.4) CH12=2300
E7107 (μM)
ABT263 (μM)
FIG. 10 CONT. 1

FIG. 10



Bcl-xl shRNA
SYNERGY SCORE =7.42
LOEWE EXCESS
DOSE MATRIX
GROWTH INHIBITION (%) N=2
E7107 (μM)
ABT263 (μM)
VOL=1.62(.61) CHI2=11
SYNERGY SCORE =7.03
VOL=.145(.6) CHI2=11
FIG. 10
FIG. 10 CONT.2
FIG. 10 CONT.
FIG. 10 CONT.1
FIG. 10 CONT.2

FIG. 10 CONT.




FIG. 10
SYNERGY SCORE =85.4
DOSE MATRIX
GROWTH INHIBITION (%) N=2
E7107 (μM)
ABT263 (μM)
A549
LOEWE EXCESS
GROWTH INHIBITION (%)
VOL=25.7(.51) CH12=5400
FIG. 10 CONT. 2
SYNERGY SCORE =35.2
NCIH1568
VOL=9.94(.62) CH12=1700
FIG. 10
FIG. 10 CONT. 1
FIG. 10 CONT.
FIG. 10 CONT. 2

FIG. 10 CONT. 1


FIG. 10 CONT.
SYNERGY SCORE =28.3
DOSE MATRIX
GROWTH INHIBITION (%) N=2
E7107 (μM)
ABT263 (μM)
LOEWE EXCESS
GROWTH INHIBITION (%)
VOL=8.56(.52) CH12=170
SYNERGY SCORE =12.7
VOL=3.79(.68) CH12=260
FIG. 10 CONT.1
FIG. 10 CONT.2
FIG. 10
FIG. 10 CONT.
FIG. 10 CONT. 2



EMPTY VECTOR
SYNERGY SCORE = 32.6
DOSE MATRIX | A549.2
GROWTH INHIBITION (%) N=1
LOEWE EXCESS | A549.2
GROWTH INHIBITION (%)
VOL=105 CH2=1e-20
BCLxL shRNA
SYNERGY SCORE = 16.4
DOSE MATRIX | A549.4
GROWTH INHIBITION (%) N=1
LOEWE EXCESS | A549.4
GROWTH INHIBITION (%)
VOL=4.81 CH2=1e-20
E7107 (μM)
ABT199 (μM)

FIG. 11



SYNERGY SCORE DOSE MATRIX
LOEWE EXCESS
H3B-8800 x NAVITOCLAX (ABT-263) H3B U266B1.1
41.3
DOSE MATRIX | U266B1.1
LOEWE EXCESS | U266B1.1
H3B-8800 (μM)
NAVITOCLAX (ABT-263) (μM)
GROWTH INHIBITION (%) N=1
GROWTH INHIBITION (%)
VOL=14.5(.56) CH12=810
FIG. 12 CONT.
FIG. 12 CONT. 1
FIG. 12
FIG. 12 CONT.
FIG. 12 CONT. 1
FIG. 12 CONT. 2

FIG. 12




FIG. 12 CONT.

FIG. 12 | FIG. 12 CONT.
FIG. 12 CONT.1 | FIG. 12 CONT.2




FIG. 12 CONT. 1

FIG. 12 | FIG. 12 CONT.
FIG. 12 CONT. 1 | FIG. 12 CONT. 2


FIG. 12 CONT.
FIG. 12 CONT. 1
FIG. 12 CONT. 2



FIG. 12 CONT.
LOEWE MODEL | RPMI8226.1
GROWTH INHIBITION (%) N=1
H3B-8800 (μM)
NAVITOCLAX (ABT-263) (μM)
FIG. 12 CONT. 1

FIG. 12 CONT. 2



SYNERGY SCORE DOSE MATRIX
LOEWE EXCESS
H3B-8800 x VENETOCLAX (ABT-199) H3B JUN3.1
26.1
DOSE MATRIX | JUN3.1
LOEWE EXCESS | JUN3.1
H3B-8800 (µM)
VENETOCLAX (ABT-199) (µM)
GROWTH INHIBITION (%) N=1
GROWTH INHIBITION (%)
VOL=15.4(.35) CH12=510
FIG. 13 CONT.
FIG. 13 CONT.1
FIG. 13 CONT. 1
FIG. 13 CONT. 2

FIG. 13




FIG. 13 CONT.

FIG. 13 | FIG. 13 CONT. | FIG. 13 CONT. 1 | FIG. 13 CONT. 2



FIG. 13
FIG. 13 CONT. 2
H3B-8800 x VENETOCLAX (ABT-199) H3B RPMI8226.1
19
DOSE MATRIX | RPMI8226.1
LOEWE EXCESS | RPMI8226.1
GROWTH INHIBITION (%) N=1
GROWTH INHIBITION (%)
VOL=12.1(.35) CH12=240
H3B-8800 (μM)
VENETOCLAX (ABT-199) (μM)
0
3.5e-5
8e-4
.0069
.061
.55
5
FIG. 13
FIG. 13 CONT.
FIG. 13 CONT. 1
FIG. 13 CONT. 2

FIG. 13 CONT. 1



FIG. 13 CONT.
FIG. 13 CONT. 1
FIG. 13 CONT. 2
LOEWE EXCESS | RPMI8266.1
GROWTH INHIBITION (%) N=1
H3B-8800 (μM)
NAVITOCLAX (ABT-199) (μM)
5
.55
.061
.0060
8e-4
3.5e-5
0
3.5e-5
8e-4
.0069
.061
.55
5

FIG. 13 CONT. 2



SYNERGY SCORE DOSE MATRIX
LOEWE EXCESS
A-1331852 (BCL-xL) x H3B-8800 H3B RPMI8226.1
68.3
DOSE MATRIX | RPMI8226.1
LOEWE EXCESS | RPMI8226.1
GROWTH INHIBITION (%) N=1
GROWTH INHIBITION (%)
VOL=33.5(.32) Ch12=1900
A-1331852 (BCL-xL) (µM)
H3B-8800 (µM)
FIG. 14 CONT.
FIG. 14 CONT.1
FIG. 14 CONT.2

FIG. 14




FIG. 14 CONT.

FIG. 14	FIG. 14 CONT.
FIG. 14 CONT. 1	FIG. 14 CONT. 2



FIG. 14
FIG. 14 CONT. 2
FIG. 14 CONT.
FIG. 14 CONT. 2
A-1331852 (BCL-xL) x H3B-8800 H3B MM1S.1
56.8
DOSE MATRIX | MM1S.1
GROWTH INHIBITION (%) N=1
A-1331852 (BCL-xL) (μM)
H3B-8800 (μM)
LOEWE EXCESS | MM1S.1
GROWTH INHIBITION (%)
VOL=27.3(.44) CH12=1800

FIG. 14 CONT. 1




FIG. 14 CONT. 2

FIG. 14 CONT. 1 | FIG. 14 CONT. 2